Latest Breaking News On - முழு ப்ரிஸ்க்ரைபிஂக் தகவல் - Page 10 : comparemela.com

Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting Data highlight the clinical effectiveness of WAKIX for excessive daytime sleepiness and cataplexy in adults with narcolepsy News provided by Share this article Share this article PLYMOUTH MEETING, Pa., June 10, 2021 /PRNewswire/  Harmony Biosciences Holdings, Inc. ( Harmony ) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced results of a new analysis evaluating number needed to treat (NNT) and effect sizes for treatment with WAKIX ® (pitolisant) that demonstrates the magnitude of its clinical effectiveness for excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The poster was presented at the 35

United statesJeffrey daynoHarmony biosciences holdings incDrug administrationHarmony biosciences holdingsAnnual meetingAssociated professional sleep societiesChief medical officerClinical benefitsExcessive daytime sleepinessAdults with narcolepsyEpworth sleepiness scaleFull prescribing informationHarmony biosciencesஒன்றுபட்டது மாநிலங்களில்நல்லிணக்கம் உயிர் அறிவியல் ஹோல்டிங்ஸ் இன்க்